- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07403539
Speech Learning and Speech Production in Parkinson's Disease
February 4, 2026 updated by: Mishaela DiNino, State University of New York at Buffalo
Relationship Between Speech Perceptual Learning and Speech Production in Parkinson's Disease
Parkinson's disease, a common movement disorder that results from a breakdown in the brain, often leads to challenges with talking, but less is known about the relationship between difficulties with talking and difficulties with learning to understand speech.
By linking these two abilities in individuals with Parkinson's disease using a precision medicine approach, this project seeks to build a basis for new therapies that help people with Parkinson's disease both understand better and speak more clearly.
Study Overview
Status
Recruiting
Conditions
Detailed Description
In the context of speech-language therapy, Parkinson's disease (PD) is typically associated with its consequences on speech production.
Interventions generally focus on learning or relearning skills to accomplish successful production.
However, the disease itself, as well as patient responses to interventions, are variable.
Individuals differ widely in how typical their speech output is before intervention and in how much they learn from treatment.
One plausible explanation for this variation comes from a less-studied aspect of speech and language in PD: speech perception, especially speech perceptual learning.
There is a key gap in the PD literature about whether people who produce atypical rate and intensity properties in their own speech also find it more difficult to learn rate and intensity properties from others' speech.
There is, therefore, a critical need for a full understanding of the relationship between speech production and speech perceptual learning in PD.
The long- term goal of this research program is to systematically interrogate the relationship between speech learning and production in people with PD and to leverage that knowledge to promote effective communication.
The overall objective of this project is to use acoustic measures to determine how challenges with speech perception or learning can predict individual differences in speech production.
The central hypothesis is that individual differences between people with PD in speech perception or learning can predict individual differences between people with PD in speech production.
This project adopts an individual differences approach to investigate two major aims: (1) relating individual differences in the perceptual learning of speech rate to the production of speech rate, and (2) relating individual differences in the perceptual learning of intensity to the production of intensity.
To investigate these aims, each participant will record a speech sample and conduct tasks that involve learning regularities in rate or intensity in the speech of others.
Participants will also complete tasks that require the ability to distinguish between sentences based on their rate and intensity.
Participants' speech samples will additionally be judged by naive listeners to assess the samples' intelligibility and the effort that it takes to understand the speakers.
If individual differences in perceptual learning predict individual differences in production, then differences in speech perception may predict differences in speech-language therapy outcomes that could be targeted to patient needs.
A precision medicine approach would allow for interventions that titrate the amount, level, and type of intervention on an individualized basis to make sure that treatments are focused on participants who will respond to them in dosages that they will benefit from.
For instance, a therapist could provide speech perception training to accelerate outcomes of production-related treatments.
Furthermore, by applying more naturalistic measures of speech perception to this population, especially ones that rely on participants to change over the course of a session, this project provides an innovative opportunity to examine the sensory and perceptual consequences of PD and to link those to better-documented motor outcomes
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14214
- Recruiting
- State University of New York at Buffalo
-
Contact:
- Jordana Maisel
- Phone Number: 1 (716) 829-5902
- Email: jlmaisel@buffalo.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of Parkinson's disease
- Native speaker of North American English
- Use a drug that includes levodopa
- Resident of the United States
Exclusion Criteria:
- Any history of language, hearing or speech disorder outside of Parkinson's disease
- Other gross neurological impairment such as Alzheimer's disease or stroke
- Significant hearing loss and/or use of a hearing aid or cochlear implant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Learning and Discrimination
Behavioral interventions will be administered, including speech intensity learning, speech intensity discrimination, speech rate learning, and speech rate discrimination
|
Participants will be asked to pair sentences that vary in their sound intensity to one of three colored squares (red, yellow, or blue)
Participants will hear two sentences that are either the same or different in their sound intensity and will be asked to indicate whether the sentences were of the same or different intensities
Participants will be asked to pair sentences that vary in their spoken rate to one of three colored squares (red, yellow, or blue)
Participants will hear two sentences that are either the same or different in their spoken rate and will be asked to indicate whether the sentences were of the same or different rates
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean dB SPL
Time Frame: Day 1
|
The mean speech intensity (in dB SPL) will be assessed using a recording of spoken sentences and a spoken paragraph.
|
Day 1
|
|
Standard deviation dB SPL
Time Frame: Day 1
|
The standard deviation of participant's speech intensity (in dB SPL) will be assessed using a recording of spoken sentences and a spoken paragraph.
|
Day 1
|
|
Speaking rate
Time Frame: Day 1
|
The speaking rate (in syllables/second) will be assessed using a recording of spoken sentences and a spoken paragraph.
|
Day 1
|
|
Articulation rate
Time Frame: Day 1
|
The articulation rate (in syllables/second after removing pauses) will be assessed using a recording of spoken sentences and a spoken paragraph.
|
Day 1
|
|
Unfilled pause time
Time Frame: Day 1
|
The unfilled pause time (in seconds of pause) will be assessed using a recording of spoken sentences and a spoken paragraph.
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 27, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2027
Study Registration Dates
First Submitted
January 27, 2026
First Submitted That Met QC Criteria
February 4, 2026
First Posted (Actual)
February 11, 2026
Study Record Updates
Last Update Posted (Actual)
February 11, 2026
Last Update Submitted That Met QC Criteria
February 4, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00008661
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified speech perception and speech production data from individual participants
IPD Sharing Time Frame
Information will be available at the conclusion of data collection and will be available indefinitely
IPD Sharing Access Criteria
Data and supporting material will be available on the Open Science Framework, a database that is open to the general public
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Universitätsklinikum Hamburg-EppendorfUniversity of Oxford; University of TwenteRecruitingDeep Brain Stimulation | Parkinson's Disease (PD)Germany
Clinical Trials on Intensity learning
-
KU LeuvenKom Op Tegen KankerEnrolling by invitationColorectal CancerBelgium
-
KU LeuvenEnrolling by invitation
-
Chelsea and Westminster NHS Foundation TrustNational Institute for Health Research, United Kingdom; OCB MediaCompletedQuality Improvement | Learning | eLearningUnited Kingdom
-
Laval UniversityUnknownLung Diseases, ObstructiveCanada
-
Sultan Qaboos Comprehensive Cancer CenterNot yet recruiting
-
University Hospital Inselspital, BerneUniversity of BernCompleted
-
Virginia Polytechnic Institute and State UniversityNational Institute of Mental Health (NIMH)Completed
-
McMaster UniversityCompleted
-
University of Wisconsin, MadisonCompleted
-
Brigham and Women's HospitalNational Institute on Aging (NIA); Boston Medical CenterCompletedDiabetes Mellitus, Type 2 | Medication AdherenceUnited States